CAJ | 학술논문

目的：探讨替莫唑胺( Temozolomide, TMZ)治疗复发脑胶质瘤的临床效果与安全性。方法选择复发脑胶质瘤42例口服TMZ起始剂量150 mg/( m2·d),连服5 d,28 d为1个周期。治疗3个周期后观察临床效果与不良反应情况。结果本组42例均顺利完成化疗,期间无1例出现治疗相关性死亡。本组15例肿瘤明显缩小,部分缓解(PR)率为35.7%(15/42)；16例肿瘤稳定,疾病稳定(SD)率为38.1%(16/42)；11例肿瘤增大,进展(PD)率为26.2%(11/42)。有效率(CR+PR)为35.7%(15/42),疾病控制率(CR+PR+SD)为73.8%(31/42)。本组21例出现恶心、呕吐症状,6例出现白细胞、中性粒细胞、血小板降低等毒性反应,2例出现不同程度脱发,但均未发生肝、肾、肺等其他重要脏器损的害。结论 TMZ对复发脑胶质瘤具有一定的临床效果,其不良反应少,是较理想的化疗用药。
목적：탐토체막서알( Temozolomide, TMZ)치료복발뇌효질류적림상효과여안전성。방법선택복발뇌효질류42례구복TMZ기시제량150 mg/( m2·d),련복5 d,28 d위1개주기。치료3개주기후관찰림상효과여불량반응정황。결과본조42례균순리완성화료,기간무1례출현치료상관성사망。본조15례종류명현축소,부분완해(PR)솔위35.7%(15/42)；16례종류은정,질병은정(SD)솔위38.1%(16/42)；11례종류증대,진전(PD)솔위26.2%(11/42)。유효솔(CR+PR)위35.7%(15/42),질병공제솔(CR+PR+SD)위73.8%(31/42)。본조21례출현악심、구토증상,6례출현백세포、중성립세포、혈소판강저등독성반응,2례출현불동정도탈발,단균미발생간、신、폐등기타중요장기손적해。결론 TMZ대복발뇌효질류구유일정적림상효과,기불량반응소,시교이상적화료용약。
Objective To evaluate the efficacy and safety of temozolomide ( TMZ) in the treatment of recurrent brain gliomas. Methods A total of 42 patients with recurrent brain glioma were treated by TMZ with a initial dosage of 150 mg/m2 once a day for durative 5 days and 28 days as a treatment cycle. The clinical curative effect and complications were observed after 3 cycles of treatment. Results The group of 42 patients was successfully completed chemotherapy, and no treatment-re-lated death occurred during the therapy. There were 15 patients with reduced tumor sizes, and the partial remission ( PR) rate was 35.7% (15/42); 16 patients with stable diseases, and the stable disease (stable disease, SD) rate was 38. 1%(16/42);11 patients with tumor growth, and the progression (progressive disease, PD) rate was 26. 2% (11/42). Efficien-cy rate (CR+PR) in the group was 35. 7% (15/42), and disease control rate (CR+PR+SD) was 73. 8% (31/42). Twenty-one patients had nausea and vomiting, and six patients had toxic reactions, such as decreased white blood cells, neu-trophils, and platelets. Two patients showed different degrees of hair loss, but no damage of liver, kidney, and lung. Conclu-sion TMZ is an ideal chemotherapy drug that can be used to treat recurrent brain glioma, because it has a certain clinical effect and less adverse reaction.